Covid-19 roundup: CDC ad­vi­so­ry com­mit­tee to dis­cuss Pfiz­er/BioN­Tech boost­ers for all adults; US buys up $1B in GSK/Vir mAbs

About a week af­ter Pfiz­er asked reg­u­la­tors to ex­pand its Covid-19 boost­er shot EUA to in­clude all adults, the CDC’s Ad­vi­so­ry Com­mit­tee on Im­mu­niza­tion Prac­tices has sched­uled a meet­ing to dis­cuss the idea.

ACIP will meet this Fri­day, and is ex­pect­ed to give an of­fi­cial rec­om­men­da­tion soon af­ter, The As­so­ci­at­ed Press re­port­ed on Tues­day.

Pfiz­er and BioN­Tech’s boost­er shot is cur­rent­ly au­tho­rized for those 65 years and old­er, or at high-risk of a Covid in­fec­tion, in­clud­ing health care work­ers and oth­ers with oc­cu­pa­tion­al haz­ards. Be­fore de­cid­ing on those lim­i­ta­tions, the FDA’s ad­vi­so­ry com­mit­tee on Vac­cines and Re­lat­ed Bi­o­log­i­cal Prod­ucts (VRB­PAC) round­ly re­ject­ed Pfiz­er/BioN­Tech boost­er shots for all in­di­vid­u­als old­er than 16 by a 16-2 vote.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER